The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

Updated findings from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study (NCT04221945) show the survival advantages of ...

XOMA Royalty recorded total income and revenues of $7.2 million for the third quarter of 2024, which included $6.5 million in estimated income associated with two commercial products in our portfolio.

During the past 20 years, the advent of neoadjuvant, primary ... compared with surgical resection with or without adjuvant treatment. Second, chemotherapy can act as a radiosensitizer, improving ...

Researchers tracked treatment stages, such as surgery, chemotherapy, and neoadjuvant chemoradiation, along with the stage at ...

The standard of care (SOC) for locally advanced OSCC involves surgical resection followed by adjuvant radiation/chemoradiation or ... None of the patients received neoadjuvant chemotherapy or any ...

Given its influence on therapy efficacy, the TME presents a promising area ... in LARC patients treated with neoadjuvant chemoradiation (nCRT). Their analysis identified gross tumor volume (GTV) and ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Organ preservation has become an attractive alternative to surgery (total mesorectal excision [TME]) among patients with rectal cancer after neoadjuvant therapy who achieve a clinical complete ...